GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc covers the month of December 2022, with a specific reporting date of December 02, 2022. The document serves as a transaction notification regarding dealings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of specific equity transactions.
Material Changes and Transactions
The filing details the grant of share options to four senior executives under the Company's Share Save Plan 2022. All transactions occurred on November 28, 2022, on the London Stock Exchange (XLON).
- Ms E Walmsley (Chief Executive Officer): Granted options over 790 Ordinary Shares at a price of £11.39.
- Mr J Ford (SVP and Group General Counsel, Legal and Compliance): Granted options over 790 Ordinary Shares at a price of £11.39.
- Mr D Redfern (President Corporate Development): Granted options over 790 Ordinary Shares at a price of £11.39.
- Ms V Whyte (Company Secretary): Granted options over 790 Ordinary Shares at a price of £11.39.
The financial instrument involved is Ordinary Shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the statutory notification of the aforementioned option grants.
Investor Verification Points
- Verify the terms and vesting schedule of the Share Save Plan 2022 referenced in the transaction.
- Confirm the market price of GSK Ordinary Shares on November 28, 2022, to assess the discount or premium of the £11.39 option price.
- Review the total number of options granted to these executives in the current fiscal year to understand cumulative dilution impact.